The majority of the Top Companies issue is just about done, dear readers! Still need to finish up some layouts and write the short intros to the two major sections (Top 20 Pharma & Top 10 Biopharma), but the finish line is actually within sight!
So I thought I’d take a break from my biopharma layouts and share with you a couple of odd laughs:
Inadvertent Pharma Phunnies
* * *
Advertent Pharma Phunnies
I needed a subhed for a section on how Enbrel has a strict warning about the possibility of TB and other infections among patients. Since Amgen has been hit with a lot of labeling and safety issues this past year, I went with “Phthisis Ridiculous!”
* * *
Huge restructuring plans with portentous names were the norm this year, leading to this paragraph from my Wyeth profile:
In 2008, Wyeth transitioned from its open-ended and somewhat ambiguous Project Springboard productivity plan into Project Impact. While the notions of â€œspringboardâ€ and â€œimpactâ€ may evoke images of Wile E. Coyote smashed flat against a cliff face, this new initiative is intended to â€œadjust down our infrastructure and reduce our operating costs in response to loss of Protonix sales in 2008 [and] to facilitate long-term growth, as well as to address short-term fiscal challenges,â€ according to the companyâ€™s 10-K statements.
Okay, maybe I’m just punchy.